Best Diabetes Drug Companies in 2025
23 Jul, 2025

The global diabetes drug market size is expected to be nearly US$ 113.63 billion by 2033, up from US$ 66.69 billion in 2024. It is growing at a CAGR of 6.10% over the 2025-2033 period. The global diabetes medication market is experiencing strong growth, driven by the rising prevalence of type 2 diabetes, increasing health awareness, and ongoing advancements in pharmaceutical research. The demand for more convenient and effective treatment options has spurred innovation in both injectable and oral therapies, including insulin analogs and newer drug classes such as SGLT-2 inhibitors and GLP-1 receptor agonists.

The shift toward combination therapies and personalized medicine is further enhancing treatment outcomes. However, the market faces several challenges, including high treatment costs, limited access in low- and middle-income countries, and growing competition from generics and biosimilars.

Despite these hurdles, the market remains dynamic, offering promising opportunities in lifestyle management support, digital health integration, and the development of novel therapies aimed at improving glucose control and overall health outcomes.

Discover key trends, growth opportunities, and major challenges shaping the Diabetes Drug Industry in Renub Research’s latest in-depth market report. Download your free sample now

List of Leading Companies in the Diabetes Drug Market

1.Novo Nordisk

Establishment: 1989

Headquarters: Denmark

Website: www.novonordisk.com

Revenue: $42.1B in 2023

Novo Nordisk AS, a subsidiary of Novo Holdings AS, is a global healthcare company specializing in the discovery, development, and delivery of biological medicines. The company focuses on therapeutic areas including diabetes, haemophilia, human growth hormone (HGH) disorders, rare blood and endocrine diseases, and obesity.

Novo Nordisk’s product portfolio includes pre-filled insulin delivery systems, glucagon emergency kits, cartridges, needles, vials, insulin formulations, estradiol for hormone replacement therapy, recombinant treatments for haemophilia, glucagon, and oral antidiabetic medications. These products are offered under well-known brands such as NovoPen, FlexPen, Saxenda, and Ozempic.

The company operates through a global network of subsidiaries, marketing its products across North America, Europe, Asia, Latin America, Africa, the Middle East, and Australia. Novo Nordisk is headquartered in Bagsværd, Denmark.

2.AstraZeneca plc

Establishment: 1999

Headquarters: United Kingdom

Website: www.astrazeneca.com

Revenue: $54.1B in 2023

AstraZeneca Plc is a global biopharmaceutical company committed to the research, development, and commercialization of prescription medicines. The company focuses on advancing treatments in key therapeutic areas including oncology, cardiovascular, renal and metabolic diseases, respiratory and immunology, as well as vaccines, immune therapies, and rare diseases.

Its product portfolio includes vaccines, biologics, and prescription drugs, which are distributed to primary and specialty care physicians through a network of distributors, local representative offices, and wholly owned marketing subsidiaries. AstraZeneca operates across Asia, Africa, Australasia, Europe, and the Americas.

To enhance drug development and streamline distribution, AstraZeneca collaborates with governments, academic institutions, and industry partners. The company is headquartered in Cambridge, Cambridgeshire, United Kingdom.

3.Biocon

Establishment: 1978

Headquarters: India

Website: www.biocon.com

Revenue: $1.8B in 2024

Biocon Ltd. is a leading biopharmaceutical company headquartered in Bangalore, Karnataka, India, specializing in the research and development of therapies for chronic conditions such as diabetes, cancer, and autoimmune diseases. The company offers a wide range of products including complex biologics, branded formulations, recombinant human insulin (rh-Insulin), insulin analogs, monoclonal antibodies (MAbs), and various active pharmaceutical ingredients (APIs).

Biocon also provides contract manufacturing, drug licensing, research and development, and small and large molecule manufacturing services to pharmaceutical and biotechnology companies worldwide. Its R&D center and manufacturing facility are located in BioXcell, Malaysia, supporting its global operations.

The company has a presence in the United States, Switzerland, the United Arab Emirates, Malaysia, the United Kingdom, and Ireland, reinforcing its international footprint in the biopharmaceutical industry.

4.Eli Lilly

Establishment: 1876

Headquarters: United States of America

Website: www.lilly.com

Revenue: $45.0B in 2023

Eli Lilly and Co. (Lilly) is a global pharmaceutical company engaged in the discovery, development, manufacturing, and commercialization of medical products for human health. The company focuses on key therapeutic areas such as neurology, immunology, oncology, and cardiometabolic health.

Lilly markets its pharmaceutical products under well-known brands including Basaglar, Humalog, Jardiance, Trulicity, Cyramza, and Emgality. These products are distributed through independent wholesale distributors to a wide range of customers, including wholesalers, pharmacy benefit managers, managed care organizations, group purchasing organizations, hospitals, government and long-term care facilities, and select retail pharmacies.

The company maintains a global presence with manufacturing, distribution, and research and development facilities across North America, South America, Europe, the Middle East, Africa, and the Asia-Pacific region. Lilly is headquartered in Indianapolis, Indiana, USA.

5.Johnson & Johnson

Establishment: 1886

Headquarters: United States of America

Website: www.jnj.com

Revenue: $88.8B in 2023

Johnson & Johnson (J&J) is a global healthcare company engaged in the research, development, manufacturing, and commercialization of innovative medicines and medical technologies. Operating through its network of subsidiaries, J&J provides pharmaceutical products targeting therapeutic areas such as immune disorders, cancer, neurological conditions, infectious diseases, cardiovascular, and metabolic disorders.

In addition to pharmaceuticals, the company offers medical devices used in cardiovascular care, orthopedics, neurovascular treatment, general surgery, and vision care. Its products are distributed to retailers, wholesalers, healthcare professionals, and hospitals worldwide.

J&J maintains manufacturing facilities across the United States, Europe, Asia-Pacific, Africa, Latin America, and the Western Hemisphere (excluding the US). The company is headquartered in New Brunswick, New Jersey, USA.

6.Bristol Myers Squibb Co.

Establishment: 1887

Headquarters: United States of America

Website: www.bms.com

Revenue: $48.3B in 2023

Bristol-Myers Squibb Co. (BMS) is a global biopharmaceutical company engaged in the research, development, licensing, manufacturing, marketing, distribution, and retail of innovative biopharmaceutical products. The company focuses on key therapeutic areas such as neurology, immunology, cardiovascular diseases, hematology, and oncology.

BMS collaborates with third parties through co-development, co-commercialization, licensing, and joint venture agreements to advance the development of select therapies. Its products are marketed under prominent brands including Opdivo, Reblozyl, Krazati, Sprycel, and Sotyktu, among others.

The company supplies its medicines to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government organizations. BMS operates manufacturing facilities in the United States, the Netherlands, Puerto Rico, Ireland, and Switzerland, with its corporate headquarters located in Princeton, New Jersey, USA.

7.Novartis AG

Establishment: 1996

Headquarters: Switzerland

Website: www.novartis.com

Revenue: $51.7B in 2023

Novartis AG, headquartered in Basel, Switzerland, is a leading global pharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative medicines. The company’s product portfolio spans a wide range of therapeutic areas, including cardiovascular, renal and metabolic diseases, immunology, ophthalmology, respiratory conditions, global health, neuroscience, and oncology.

Novartis markets its products worldwide under well-known brands such as Entresto, Cosentyx, Kesimpta, Kisqali, and Tasigna, among others. Its customer base includes pharmacists, private healthcare providers, government agencies, physicians, hospitals, insurance companies, managed care organizations, pharmacy benefit managers, and public healthcare systems.

The company operates manufacturing facilities across several countries, including the United States, Switzerland, Austria, Slovenia, China, France, and Italy, supporting its global distribution network.